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1. Introduction 
Because of their charge mobility, highly-conjugated 
polycyclic compounds are important in practical applications for 
electronic materials, such as in dye lasers and electroluminescent 
materials.1-5 Compounds with a cyclic amidine moiety, such as 
fused perimidine derivatives,6 are particularly useful because 
they have high π-stacking ability, electron affinity, and reduction 


































Scheme 1. Strategy for direct synthesis of highly fused 
perimidines 
 
We have an ongoing program directed toward fused 
isoquinoline synthesis based on four-component coupling and 
cyclization cascade (Scheme 1, eq 1).10,11 We postulated that a 
fused perimidine skeleton could be readily constructed by 
copper-catalyzed annulation of 2-ethynylbenzaldehyde 1 with 
1,8-diaminonaphthalene 2 (eq 2). Use of 2-alkynylbenzaldehydes 
1 bearing an aryl halide moiety (X = halogen) with palladium-
catalyzed C–H arylation4,5,12-21 of the resulting perimidines 3 





































Scheme 2. Related reactions for synthesis of fused isoquinolines 
 
Recently, several syntheses of isoquinoline-fused compounds 
using a diamine component have been reported (Scheme 2). 
Dyker et al. used 1,2-phenylenediamine for construction of a 
benzimidazo[2,1-a]isoquinoline skeleton from 2-
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A novel synthesis of highly fused perimidine derivatives was achieved in two steps from 2-
alkynylbenzaldehydes. Copper-catalyzed annulation of 2-[(2-
bromophenyl)ethynyl]benzaldehydes with 1,8-diaminonaphthalene produced dihydroisoquino-
lino[2,1-a]perimidines bearing a 2-bromophenyl group. Subsequent palladium-catalyzed C-H 
arylation provided dibenzo[1,2:7,8]quinolizino[3,4,5,6-kla]perimidine derivatives in moderate to 
good yields.  
 









alkynylbenzaldehydes (eq 3).22,23 Yanada et al. reported 
palladium-catalyzed direct synthesis of benzimidazo[2,1-
a]isoquinolines through one-pot Sonogashira coupling between 
2-bromobenzaldehydes and an alkyne, followed by cyclization 
with 1,2-phenylenediamine (eq 4).24 Sridhar et al. reported a 
gold-catalyzed reaction of 2-alkynylbenzaldehydes with aniline, 
which had another nucleophilic functionality such as 
pyrrole/indole/imidazole rings or amino/sulfonamide/hydroxy 
groups (eq 5).25 However, annulation of 2-alkynylbenzaldehydes 
with a diamine component in which each of amino groups is 
located on a different benzene ring is unprecedented.26 Here, we 
report a novel synthesis of highly fused perimidines 4 by copper-
catalyzed coupling and cyclization of 2-alkynylbenzaldehydes 1 
and 1,8-diaminonaphthalene 2, followed by palladium-catalyzed 
C–H arylation (Scheme 1). 
 
2. Results and discussion  
The reaction conditions for the copper-catalyzed annulation 
using 2-[(2-bromophenyl)ethynyl]benzaldehyde 1a and 1,8-
diaminonaphthalene 2 were optimized (Table 1). When the 
aldehyde 1a was treated with 2 in the presence of  CuI (10 
mol %) in DMF, the isoquinoline 6 was obtained as the oxidized 
form in 53% yield (entry 1). The use of dioxane as the solvent at 
80 °C under an Ar or O2 atmosphere was less effective, and 
produced the intermediate aminal 5 as the major product (56–
67% yield) along with unoxidized isoquinoline 3a (18–20% yield, 
entries 2 and 3). Although the reaction at higher temperature 
(120 °C) increased the yield of 3a to 92% (entry 4), scaling up 
the reaction from 0.11 mmol to 1.1 mmol was unsuccessful 
(entry 5). The use of microwave irradiation solved this problem, 
and 3a was produced in 91% yield on the 1.1 mmol scale (entry 
6). Because microwave conditions in DMF led to an 
unsatisfactory result (entry 7), the conditions shown in entry 6 
were used for further investigations. 


























entry solvent conditions 
yield (%)c 
3a 5 6 7
1 DMF 110 °C, 20 h - - 53 - 
2 dioxane 80 °C, 10 h 20 67 - - 
3d dioxane 80 °C, 30 h 18 56 7 - 
4 dioxane reflux, 12 h 92 - - 5 
5e dioxane reflux, 24 h 54 34 - - 
6e dioxane MWb, 150 °C, 60 min 91 - - 5 
7 DMF MWb, 140 °C, 60 min 56 - 7 31
aUnless otherwise stated the reactions were conducted with 1a (0.11 mmol) 
and 2 (1.2 equiv) in the presence of CuI (10 mol %) under Ar. 
bMW=microwave irradiation. c Isolated yields. dThe reaction was conducted 
under an O2 atmosphere. e The reactions were conducted on a 1.1 mmol scale. 
The substrate scope of the copper-catalyzed annulation was 
then examined using substituted 2-alkynylbenzaldehydes 1b–h 
(Table 2). These substrates were readily prepared by Sonogashira 
coupling of substituted 2-ethynylbenzaldehydes with 2-
iodobromobenzene (see the experimental section). The substrates 
1b–e, bearing an electron-withdrawing (fluoro) or -donating 
(methyl or methoxy) substituent at the para- or meta-position to 
the formyl group, underwent the desired annulation under the 
standard reaction conditions. The corresponding fused 
perimidines 3b–e were produced in good to excellent yields (71–
97%, entries 1–4). Substitution with a fluoro group at the ortho 
position was also tolerated (entry 5). Influence of the benzene 
substitution at the alkyne terminus with a fluoro or methyl group 
was less important (entries 6 and 7). The substrates 1i and 1j 
without a bromo substituent also gave the desired products 3i and 
3j in high yields (91%, entries 8 and 9). 
Table 2. Coupling–cyclization of various 2-
alkynylbenzaldehydesa 
a Compounds 1 (50 mg) and 2 (1.5 equiv) in dioxane were stirred for 1 h at 
150 °C under microwave irradiation in the presence of CuI (10 mol %). b 
Isolated yields. 













1 1b/3b: R1 = F, R2 = H 97 
2 1c/3c: R1 = Me, R2 = H 97 
3 1d/3d: R1 = H, R2 = F 89 
























6 1g/3g: R = F 73 










8 1i/3i: R = H 91 
9 1j/3j: R = Me 91 
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entry catalyst ligand solvent base temp. time yield (%)b 
1 Pd(OAc)2 PPh3 dioxane Cs2CO3 reflux 5 h 40 
2 Pd(OAc)2 P(t-Bu)3·HBF4 dioxane Cs2CO3 reflux 5 h 43 
3 Pd(OAc)2 none dioxane Cs2CO3 reflux 5 h 0 
4 Pd(OAc)2 PPh3 dioxane Cs2CO3 MW,c 160 °C 15 min 27 
5 Pd(OAc)2 PPh3 DMF Cs2CO3 130 °C 4 h 65 
6 Pd(OAc)2 P(t-Bu)3·HBF4 DMF Cs2CO3 130 °C 6 h 56 
7 Pd(PPh3)2Cl2 PPh3 DMF Cs2CO3 130 °C 5 h 22 
8 Pd(PPh3)4 PPh3 DMF Cs2CO3 130 °C 5 h 0 
9 Pd(OAc)2 PPh3 toluene Cs2CO3 reflux 6 h <60d 
10 Pd(OAc)2 PPh3 DMSO Cs2CO3 130 °C 6 h <65d 
11 Pd(OAc)2 PPh3 propan-2-ol Cs2CO3 reflux 6 h 0 
12 Pd(OAc)2 PPh3 EtOH Cs2CO3 reflux 4 h 0 
13 Pd(OAc)2 PPh3 DMF Na2CO3 130 °C 4 h 39 
14 Pd(OAc)2 PPh3 DMF K2CO3 130 °C 4 h <57d 
15 Pd(OAc)2 PPh3 DMF K3PO4 130 °C 4 h 78 
16 Pd(OAc)2 PPh3 DMF KOAc 130 °C 4 h <60d 
aAll reactions were conducted using 3a (0.06–0.07 mmol) in the presence of a palladium catalyst (10 mol %), ligand (25 mol %), and base (2 equiv). 
bIsolated yields. cMW=microwave irradiation. dContained inseparable impurities.  
 
In order to expand the use of 1,8-diaminonaphthalene 2 as a 
precursor of other perimidine derivatives, we examined four-
component annulation using 2-ethynylbenzaldehyde 8, 
formaldehyde 9, and secondary amine 10. As shown in Table 3, 
the reaction with diisopropylamine, piperidine, and morpholine 
as the secondary amine component produced perimidines 11a–c 
bearing an aminomethyl group (52–70% yield). 

















entry R2NH conditionsb product yield (%)c 










rt, 4 h 11c 61 
aAfter the three-component reaction of 8 (0.23 mmol), 9 (2 equiv), and 10 (2 
equiv) in the presence of CuI (10 mol %) in dioxane, 2 (3 equiv) was added 
and the reaction mixture was stirred for 1 h at 150 °C under microwave 
irradiation. bConditions for the reaction of 8 with 9 and 10. cIsolated yields. 
Next, palladium-catalyzed C–H arylation for the synthesis of 
highly fused perimidines was investigated. Isoquinoline 3a was 
chosen as the model substrate for optimization of the cyclization 
conditions (Table 4). When isoquinoline 3a was allowed to react 
with Pd(OAc)2 (10 mol %) in the presence of PPh3 (25 mol %) 
and Cs2CO3 (2 equiv) in dioxane, the desired heptacyclic 
perimidine 4a as the oxidized form was obtained in 40% yield 
(entry 1). The use of P(t-Bu)3·HBF4 as a ligand slightly improved 
the yield (43%, entry 2). Reaction in the absence of phosphine as 
the ligand (entry 3) or under microwave irradiation at 160 °C 
(entry 4) was less effective. DMF was promising as the reaction 
solvent, and produced 4a in 65% yield (entry 5). Among the 
palladium catalysts and phosphine ligands tested (entries 5–8), 
Pd(OAc)2/PPh3 was the most effective in DMF (entry 5). Other 
solvents (toluene, DMSO, propan-2-ol, and EtOH, entries 9–12) 
and bases (Na2CO3, K2CO3, K3PO4, and KOAc, entries 13–16) 
were also examined, and K3PO4 in DMF was the most effective 
(78% yield, entry 15). 
Finally, a series of substrates with various substituent patterns 
were applied to the C–H arylation under the optimized conditions 
for 3a (Table 5). All the substituted substrates 3b–h afforded the 
desired products 4b–h as the oxidized form (45–62% yield, 
entries 1–7). This result was independent of the substituents on 
the two benzene rings. The moderate yields were partly because 
crystallization was required for purification. Poor solubility of 4 
in various nonpolar or polar solvents, including aromatic solvents, 
did not allow easy purification by column chromatography. 
Tetrahedron 4 
These results show that copper-catalyzed annulation of 2-
alkynylbenzaldenydes 1 with 1,8-diaminonaphthalene 2, and 
subsequent palladium-catalyzed arylation provides convenient 
access to highly fused perimidine derivatives. 























R1 R2 R3 R4 yield (%)b 
1 3b/4b F H H H 45 
2 3c/4c Me H H H 53 
3 3d/4d H F H H 53 
4 3e/4e H OMe H H 61 
5 3f/4f H H F H 51 
6 3g/4g H H H F 49 
7 3h/4h H H H Me 62 
aAll reactions were conducted with 3 (30 mg) in the presence of K3PO4 (2 




Fused perimidine derivatives were synthesized by copper-
catalyzed annulation of 2-alkynylbenzaldenydes 1 with 1,8-
diaminonaphthalene 2. The four-component approach was 
applied to this reaction to produce perimidine derivatives bearing 
an aminomethyl group. Palladium-catalyzed C-H arylation of 
perimidines bearing an aryl bromide moiety produced a new 





1H NMR spectra were recorded using a JEOL AL-500 
spectrometer at 500 MHz frequency. Chemical shifts are reported 
in δ(ppm) relative to Me4Si (in CDCl3 or CD3OD) as internal 
standard. 13C NMR spectra were recorded using a JEOL AL-500 
and referenced to the residual CHCl3 or MeOH signal. Melting 
points were measured by a hot stage melting points apparatus 
(uncorrected). For column chromatography, Wakogel C-300E 
was employed. Microwave reaction was conducted in a sealed 
glass vessel (capacity 10 mL) using CEM Discover microwave 
reactor with a run time of no more than 10 min at below 300 W. 
The commercially available compounds including 2, 9, 10a–c, 
13a–e, and 14 were used without further purification. 
The compounds 12a–e10 and 12f27 were prepared according to the 
literature. 
 
















4.2.1. 2-[(2-Bromophenyl)ethynyl]benzaldehyde (1a). A mixture 
of 2-ethynylbenzaldehyde (12a) (1.00 g, 7.68 mmol), 1-bromo-2-
iodobenzene (13a) (1.18 mL, 9.22 mmol), CuI (146 mg, 0.77 
mmol), PdCl2(PPh3)2 (107 mg, 0.15 mmol), and Et3N (15 mL) in 
THF (15 mL) was stirred at 80 °C for 2 h under argon, and 
filtrated through a pad of celite. The filtrate was concentrated 
under reduced pressure and the residue was purified by column 
chromatography over silica gel with hexane–EtOAc (15:1) to 
give 1a (1.81 g, 83%) as a colorless solid: mp 69 °C; 1H NMR 
(500 MHz, CDCl3) δ 7.23 (ddd, J = 8.0, 8.0, 1.7 Hz, 1H, Ar), 
7.33 (ddd, J = 8.0, 8.0, 1.1 Hz, 1H, Ar), 7.48 (dd, J = 8.0, 8.0 Hz, 
1H, Ar), 7.58-7.62 (m, 2H, Ar), 7.64 (dd, J = 8.0, 1.1 Hz, 1H, Ar), 
7.70 (d, J = 8.0 Hz, 1H, Ar), 7.97 (dd, J = 8.0, 1.1 Hz, 1H, Ar), 
10.76 (s, 1H, CHO); 13C NMR (125 MHz, CDCl3) δ 89.3, 94.6, 
124.6, 125.8, 126.5, 127.2 (2C), 129.0, 130.1, 132.6, 133.4, 133.5, 
133.8, 136.1, 191.9. Anal. Calcd. for C15H9BrO: C, 63.18; H, 
3.18. Found: C, 63.20; H, 3.28. 
4.2.2. 2-[(2-Bromophenyl)ethynyl]-4-fluorobenzaldehyde (1b). 
By a procedure identical with that described for the preparation 
of 1a, 2-ethynyl-4-fluorobenzaldehyde (12b) (100 mg, 0.68 
mmol) was converted to 1b (169 mg, 83%) by the reaction with 
1-bromo-2-iodobenzene (13a) (104 μL, 0.81 mmol), CuI (6.4 mg, 
0.034 mmol), PdCl2(PPh3)2 (23.7 mg, 0.034 mmol), and Et3N 
(1.0 mL) in THF (1.0 mL) at 80 °C for 1.5 h: colorless solid: mp 
109 °C; 1H NMR (500 MHz, CDCl3) δ 7.17 (ddd, J = 8.0, 8.0, 2.1 
Hz, 1H, Ar), 7.26 (ddd, J = 8.0, 8.0, 1.7 Hz, 1H, Ar), 7.33-7.38 
(m, 2H, Ar), 7.60 (dd, J = 8.0, 1.7 Hz, 1H, Ar), 7.65 (d, J = 8.0 
Hz, 1H, Ar), 8.00 (dd, J = 8.6, 5.7 Hz, 1H, Ar), 10.67 (s, 1H, 
CHO); 13C NMR (125 MHz, CDCl3) δ 88.0 (d, J = 2.4 Hz), 95.6, 
116.9 (d, J = 21.6 Hz), 119.8 (d, J = 22.8 Hz), 124.1, 125.9, 
127.2, 128.9 (d, J = 10.8 Hz), 130.0 (d, J = 9.6 Hz), 130.5, 132.7, 
132.9, 133.6, 165.6 (d, J = 256.7 Hz), 190.2. Anal. Calcd. for 
C15H8BrFO: C, 59.43; H, 2.66. Found: C, 59.49; H, 2.80. 
4.2.3. 2-[(2-Bromophenyl)ethynyl]-4-methylbenzaldehyde (1c). 
By a procedure identical with that described for the preparation 
of 1a, 2-ethynyl-4-methylbenzaldehyde (12c) (50 mg, 0.35 
mmol) was converted to 1c (78 mg, 75%) by the reaction with 1-
bromo-2-iodobenzene (13a) (53.4 μL, 0.42 mmol), CuI (3.3 mg, 
0.017 mmol), PdCl2(PPh3)2 (12.2 mg, 0.017 mmol), and Et3N 
(0.75 mL) in THF (0.75 mL) at 80 °C for 1 h: colorless solid: mp 
79 °C; 1H NMR (500 MHz, CDCl3) δ 2.43 (s, 3H, CCH3) 7.22 
(ddd, J = 8.0, 8.0, 1.5 Hz, 1H, Ar), 7.27 (d, J = 8.0 Hz, 1H, Ar), 
7.32 (ddd, J = 8.0, 8.0, 1.1 Hz, 1H, Ar), 7.50 (s, 1H, Ar), 7.58 (dd, 
J = 8.0, 1.7 Hz, 1H, Ar), 7.63 (dd, J = 8.0, 1.1 Hz, 1H, Ar), 7.86 
(d, J = 8.0 Hz, 1H, Ar), 10.69 (s, 1H, CHO); 13C NMR (125 MHz, 
CDCl3) δ 21.6, 89.5, 94.1, 124.7, 125.8, 126.4, 127.1, 127.2, 
130.0 (2C), 132.6, 133.4, 133.7, 134.0, 144.8, 191.5. Anal. Calcd. 
for C16H11BrO: C, 64.24 H, 3.71. Found: C, 64.15; H, 3.82. 
4.2.4. 2-[(2-Bromophenyl)ethynyl]-5-fluorobenzaldehyde (1d). 
By a procedure identical with that described for the preparation 
of 1a, 2-ethynyl-5-fluorobenzaldehyde (12d) (100 mg, 0.68 
mmol) was converted to 1d (174 mg, 85%) by the reaction with 
1-bromo-2-iodobenzene (13a) (104 μL, 0.81 mmol), CuI (6.4 mg, 
0.034 mmol), PdCl2(PPh3)2 (23.7 mg, 0.034 mmol), and Et3N 
(1.0 mL) in THF (1.0 mL) at 80 °C for 1.5 h: colorless solid: mp 
93 °C; 1H NMR (500 MHz, CDCl3) δ 7.24 (ddd, J = 7.7, 7.7, 1.5 
Hz, 1H, Ar), 7.28-7.34 (m, 2H, Ar), 7.58 (dd, J = 7.7, 1.4 Hz, 1H, 
 5
Ar), 7.62-7.64 (m, 2H, Ar), 7.69 (dd, J = 8.6, 5.2 Hz, 1H, Ar), 
10.70 (d, J = 3.4 Hz, 1H, CHO); 13C NMR (125 MHz, CDCl3) δ 
88.2, 94.4, 113.7 (d, J = 22.8 Hz), 121.3 (d, J = 22.8 Hz), 122.5 
(d, J = 3.6 Hz), 124.4, 125.7, 127.2, 130.2, 132.6, 133.4, 135.4 (d, 
J = 7.2 Hz), 138.1 (d, J = 7.2 Hz), 162.6 (d, J = 253.1 Hz), 190.6. 
Anal. Calcd. for C15H8BrFO: C, 59.43; H, 2.66. Found: C, 59.60; 
H, 2.92. 
4.2.5. 2-[(2-Bromophenyl)ethynyl]-5-methoxylbenzaldehyde (1e). 
By a procedure identical with that described for the preparation 
of 1a, 2-ethynyl-5-methoxybenzaldehyde (12e) (100 mg, 0.62 
mmol) was converted to 1e (167 mg, 85%) by the reaction with 
1-bromo-2-iodobenzene (13a) (95.9 μL, 0.75 mmol), CuI (5.9 mg, 
0.031 mmol), PdCl2(PPh3)2 (21.9 mg, 0.031 mmol), and Et3N 
(1.0 mL) in THF (1.0 mL) at 80 °C for 1 h: colorless solid: mp 
102 °C; 1H NMR (500 MHz, CDCl3) δ 3.88 (s, 3H, CH3), 7.14 
(dd, J = 8.6, 2.9 Hz, 1H, Ar), 7.20 (ddd, J = 7.7, 7.7, 1.3 Hz, 1H, 
Ar), 7.31 (ddd, J = 7.7, 7.7, 1.1 Hz, 1H, Ar), 7.44 (d, J = 2.9 Hz, 
1H, Ar), 7.56 (dd, J = 8.0, 1.7 Hz, 1H, Ar), 7.60-7.63 (m, 2H, Ar), 
10.72 (s, 1H, CHO); 13C NMR (125 MHz, CDCl3) δ 55.6, 89.4, 
93.3, 109.8, 119.1, 121.7, 124.9, 125.6, 127.1, 129.7, 132.5, 
133.2, 134.7, 137.6, 160.1, 191.8. Anal. Calcd. for C16H11BrO2: C, 















4.2.6. 2-[(2-Bromophenyl)ethynyl]-6-fluorobenzaldehyde (1f). 
By a procedure similar to that described for the preparation of 1a, 
2-fluoro-6-iodobenzaldehyde (12f) (50 mg, 0.20 mmol) was 
converted to 1f (56 mg, 92%) by the reaction with 1-bromo-2-
ethynybenzene (14) (43.4 mg, 0.24 mmol), CuI (1.9 mg, 0.012 
mmol), PdCl2(PPh3)2 (7.0 mg, 0.012 mmol), and Et3N (0.5 mL) 
in THF (0.5 mL) at 50 °C for 2 h: colorless solid: mp 74 °C; 1H 
NMR (500 MHz, CDCl3) δ 7.16 (ddd, J = 7.7, 7.7, 3.6 Hz, 1H, 
Ar), 7.24 (ddd, J = 7.7, 7.7, 1.7 Hz, 1H, Ar), 7.33 (ddd, J = 7.7, 
7.7, 1.1 Hz, 1H, Ar), 7.50-7.57 (m, 2H, Ar), 7.61-7.64 (m, 2H, 
Ar), 10.70 (s, 1H, CHO); 13C NMR (125 MHz, CDCl3) δ 89.2 (d, 
J = 4.8 Hz), 95.2, 117.2 (d, J = 21.6 Hz), 124.4 (d, J = 9.6 Hz), 
125.8, 127.0, 127.1 (d, J = 25.2 Hz), 129.7 (2C), 130.4, 132.6, 
133.7, 134.8 (d, J = 10.8 Hz), 162.4 (d, J = 262.7 Hz), 188.5. 
Anal. Calcd. for C15H8BrFO: C, 59.43; H, 2.66. Found: C, 59.42; 
H, 2.93. 
4.2.7. 2-[(2-Bromo-5-fluorophenyl)ethynyl]benzaldehyde (1g). 
By a procedure identical with that described for the preparation 
of 1a, 2-ethynylbenzaldehyde (12a) (100 mg, 0.77 mmol) was 
converted to 1g (177 mg, 91%) by the reaction with 1-bromo-4-
fluoro-2-iodobenzene (13b) (83.7 μL, 0.64 mmol), CuI (6.1 mg, 
0.032 mmol), PdCl2(PPh3)2 (22.5 mg, 0.032 mmol), and Et3N 
(1.5 mL) in THF (1.5 mL) at 50 °C for 2 h: colorless solid: mp 
89–90 °C; 1H NMR (500 MHz, CDCl3) δ 6.96 (ddd, J = 8.3, 8.3, 
3.1 Hz, 1H, Ar), 7.29 (dd, J = 8.3, 2.9 Hz, 1H, Ar), 7.49 (dd, J = 
7.4, 7.4 Hz, 1H, Ar), 7.55-7.61 (m, 2H, Ar), 7.68 (d, J = 7.4 Hz, 
1H, Ar), 7.96 (dd, J = 7.4, 1.1 Hz, 1H, Ar), 10.71 (s, 1H, CHO); 
13C NMR (125 MHz, CDCl3) δ 90.2, 93.4 (d, J = 3.6 Hz), 117.7 
(d, J = 22.8 Hz), 112.1 (d, J = 24.0 Hz), 120.3 (d, J = 3.6 Hz), 
125.7, 126.0 (d, J = 9.6 Hz), 127.2, 129.3, 133.4, 133.7, 133.8 (d, 
J = 9.6 Hz), 136.2, 161.3 (d, J = 248.3 Hz), 191.4. Anal. Calcd. 
for C15H8BrFO: C, 59.43; H, 2.66. Found: C, 59.64; H, 2.95. 
4.2.8. 2-[(2-Bromo-5-methylphenyl)ethynyl]benzaldehyde (1h). 
By a procedure identical with that described for the preparation 
of 1a, 2-ethynylbenzaldehyde (12a) (200 mg, 1.54 mmol) was 
converted to 1h (331 mg, 72%) by the reaction with 1-bromo-2-
iodo-4-methylbenzene (13c) (182 μL, 1.28 mmol), CuI (12.2 mg, 
0.064 mmol), PdCl2(PPh3)2 (44.9 mg, 0.064 mmol), and Et3N 
(3.0 mL) in THF (3.0 mL) at 80 °C for 1 h: colorless solid: mp 
93–94 °C; 1H NMR (500 MHz, CDCl3) δ 2.33 (s, 3H, CCH3), 
7.04 (dd, J = 8.0, 2.0 Hz, 1H, Ar), 7.42 (d, J = 1.7 Hz, 1H, Ar), 
7.46-7.51 (m, 2H, Ar), 7.60 (ddd, J = 7.4, 7.4, 1.1 Hz, 1H, Ar),  
7.69 (d, J = 8.0 Hz, 1H, Ar), 7.97 (dd, J = 8.0, 1.1 Hz, 1H, Ar), 
10.76 (s, 1H, CHO); 13C NMR (125 MHz, CDCl3) δ 20.7, 88.9, 
94.9, 122.4, 124.2, 126.6, 127.1, 128.9, 131.2, 132.3, 133.3, 
133.7, 134.0, 136.1, 137.2, 192.0. Anal. Calcd. for C16H11BrO: C, 
64.24 H, 3.71. Found: C, 64.44; H, 3.88. 
4.2.9. 2-(Phenylethynyl)benzaldehyde (1i). By a procedure 
identical with that described for the preparation of 1a, 2-
ethynylbenzaldehyde (12a) (100 mg, 0.77 mmol) was converted 
to 1i (111 mg, 70%) by the reaction with iodobenzene (13d) (103 
μL, 0.92 mmol), CuI (7.3 mg, 0.038 mmol), PdCl2(PPh3)2 (26.9 
mg, 0.038 mmol), and Et3N (1.0 mL) in THF (1.0 mL) at 80 °C 
for 1 h: yellow oil; 1H NMR (500 MHz, CDCl3) δ 7.37-7.39 (m, 
3H, Ar), 7.44 (dd, J = 7.7, 7.7 Hz, 1H, Ar), 7.55-7.59 (m, 3H, Ar), 
7.64 (d, J = 7.4 Hz, 1H, Ar), 7.95 (d, J = 7.4 Hz, 1H, Ar), 10.65 
(s, 1H, CHO); 13C NMR (125 MHz, CDCl3) δ 84.9, 96.3, 122.3, 
126.8, 127.2, 128.5 (2C), 128.6, 129.0, 131.7 (2C), 133.2, 133.7, 
135.8, 191.6; HRMS (FAB) calcd for C15H11O (MH+): 207.0810; 
found: 207.0810. 
4.2.10. 2-[(4-Methylphenyl)ethynyl]benzaldehyde (1j). By a 
procedure identical with that described for the preparation of 1a, 
2-ethynylbenzaldehyde (12a) (100 mg, 0.77 mmol) was 
converted to 1j (120 mg, 71%) by the reaction with 1-iodo-2-
methylbenzene (13e) (201 mg, 0.92 mmol), CuI (7.3 mg, 0.038 
mmol), PdCl2(PPh3)2 (26.9 mg, 0.038 mmol), and Et3N (1.0 mL) 
in THF (1.0 mL) at 80 °C for 1 h: colorless solid: mp 48 °C; 1H 
NMR (500 MHz, CDCl3) δ 2.37 (s, 3H, CCH3), 7.18 (d, J = 8.0 
Hz, 2H, Ar), 7.40-7.46 (m, 3H, Ar), 7.56 (ddd, J = 7.6, 7.6, 1.3 
Hz, 1H, Ar), 7.62 (d, J = 6.9 Hz, 1H, Ar), 7.93 (dd, J = 7.6, 1.1 
Hz, 1H, Ar), 10.65 (s, 1H, CHO); 13C NMR (125 MHz, CDCl3) δ 
21.5, 84.3, 96.6, 119.2, 127.1 (2C), 128.3, 129.2 (2C), 131.5 (2C), 
133.1, 133.7, 135.7, 139.3, 191.7. Anal. Calcd. for C16H12O: C, 
87.25; H, 5.49. Found: C, 87.11; H, 5.74. 
4.3. Copper-catalyzed coupling–cyclization 
4.3.1. General procedure: synthesis of 13-(2-Bromophenyl)-
7,7a,12,13-dihydroisoquinolino[2,1-a]perimidine (3a) (Table 1, 
entry 6). A mixture of 1a (50 mg, 0.18 mmol), 1,8-
diaminonaphthalene (2) (41.5 mg, 0.26 mmol), and CuI (3.3 mg, 
0.018 mmol) in dioxane (1.0 mL) was stirred for 60 min at 
150 °C under microwave irradiation (300 W). The reaction 
mixture was concentrated under reduced pressure and purified by 
column chromatography over silica gel with hexane–EtOAc 
(15:1) to give 3a (68 mg, 91%) as a pale yellow amorphous solid; 
1H NMR (500 MHz, CDCl3) δ 4.49 (br s, 1H, NH), 5.68 (s, 1H, 
NCHN), 6.15 (s, 1H, C=CH), 6.36 (d, J = 7.4 Hz, 1H, Ar), 6.66 
(dd, J = 6.6, 2.0 Hz, 1H, Ar), 6.96 (dd, J = 8.0, 8.0 Hz, 1H, Ar), 
7.04-7.09 (m, 3H, Ar), 7.16 (d, J = 7.4 Hz, 1H, Ar), 7.21 (ddd, J 
= 7.4, 7.4, 1.1 Hz, 1H, Ar), 7.29-7.36 (m, 4H, Ar), 7.38-7.40 (m, 
2H, Ar); 13C NMR (125 MHz, CDCl3) δ 69.3, 103.2, 107.6, 117.1, 
118.5, 120.1, 123.0, 124.2, 124.4, 124.9, 125.8, 126.3, 126.4, 
126.6, 126.7, 129.2 (2C), 131.9, 132.2, 132.3, 134.4, 137.8, 138.3, 
142.1, 142.4; HRMS (FAB) calcd for C25H18BrN2 (MH+): 
425.0653; found: 425.0649. 
4.3.2. 13-(2-Bromophenyl)-10-fluoro-7,7a-
dihydroisoquinolino[2,1-a]perimidine (3b) (Table 2, entry 1). By 
a procedure identical with that described for the preparation of 3a, 
1b (50 mg, 0.17 mmol) was converted into 3b (70 mg, 97%) by 
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the reaction with 1,8-diaminonaphthalene (2) (39.1 mg, 0.25 
mmol) and CuI (3.1 mg, 0.017 mmol): yellow amorphous solid; 
1H NMR (500 MHz, CDCl3) δ 4.45 (br s, 1H, NH), 5.57 (s, 1H, 
NCHN), 6.12 (s, 1H, C=CH), 6.32 (d, J = 7.4 Hz, 1H, Ar), 6.67 
(dd, J = 6.9, 1.7 Hz, 1H, Ar), 6.82 (dd, J = 9.5, 2.6 Hz, 1H, Ar), 
6.88 (ddd, J = 8.6, 8.6, 2.3 Hz, 1H, Ar), 6.93 (dd, J = 8.0, 8.0 Hz, 
1H, Ar), 7.04-7.10 (m, 3H, Ar), 7.26-7.32 (m, 3H, Ar), 7.37-7.38 
(m, 2H, Ar); 13C NMR (125 MHz, CDCl3) δ 69.0, 102.2, 108.0, 
110.4 (d, J = 21.6 Hz), 112.5 (d, J = 22.8 Hz), 117.5, 118.8, 
120.3, 122.1 (d, J = 2.4 Hz), 123.5, 124.4, 124.9, 126.5, 126.8, 
128.5 (d, J = 9.6 Hz), 129.5, 131.9, 132.4, 134.5, 134.6 (d, J = 
9.6 Hz), 137.6, 138.0, 142.0, 143.7, 163.5 (d, J = 245.9 Hz); 
HRMS (FAB) calcd for C25H17BrFN2 (MH+): 443.0560; found: 
443.0558. 
4.3.3. 13-(2-Bromophenyl)-10-methyl-7,7a-
dihydroisoquinolino[2,1-a]perimidine (3c) (Table 2, entry 2). By 
a procedure identical with that described for the preparation of 3a, 
1c (50 mg, 0.17 mmol) was converted into 3c (71 mg, 97%) by 
the reaction with 1,8-diaminonaphthalene (2) (39.6 mg, 0.25 
mmol) and CuI (3.2 mg, 0.017 mmol): yellow amorphous solid; 
1H NMR (500 MHz, CDCl3) δ 2.35 (s, 3H, CCH3), 4.43 (br s, 1H, 
NH), 5.59 (s, 1H, NCHN), 6.10 (s, 1H, C=CH), 6.29 (d, J = 7.4 
Hz, 1H, Ar), 6.64 (dd, J = 6.9, 1.1 Hz, 1H, Ar), 6.92 (dd, J = 7.7, 
7.7 Hz, 1H, Ar), 6.95 (br s, 1H, Ar), 7.00-7.07 (m, 4H, Ar), 7.20 
(d, J = 7.4 Hz, 1H, Ar), 7.24-7.30 (m, 2H, Ar), 7.34 (d, J = 8.0 
Hz, 1H, Ar), 7.37 (d, J = 7.4 Hz, 1H, Ar); 13C NMR (125 MHz, 
CDCl3) δ 21.3, 69.3, 103.2, 107.6, 117.2, 118.5, 120.2, 123.0, 
123.8, 124.5, 124.8, 124.9, 126.4, 126.6, 126.7 (2C), 129.2, 132.0, 
132.1, 132.4, 134.5, 138.0, 138.5, 139.0, 142.3, 142.4; HRMS 
(FAB) calcd for C26H20BrN2 (MH+): 439.0810; found: 439.0805. 
4.3.4. 13-(2-Bromophenyl)-9-fluoro-7,7a-
dihydroisoquinolino[2,1-a]perimidine (3d) (Table 2, entry 3). By 
a procedure identical with that described for the preparation of 3a, 
1d (50 mg, 0.17 mmol) was converted into 3d (65 mg, 89%) by 
the reaction with 1,8-diaminonaphthalene (2) (39.1 mg, 0.25 
mmol) and CuI (3.1 mg, 0.017 mmol): yellow amorphous solid; 
1H NMR (500 MHz, CDCl3) δ 4.50 (br s, 1H, NH), 5.67 (s, 1H, 
NCHN), 6.09 (s, 1H, C=CH), 6.31 (d, J = 7.4 Hz, 1H, Ar), 6.69 
(dd, J = 6.6, 1.4 Hz, 1H, Ar), 6.93 (dd, J = 7.7, 7.7 Hz, 1H, Ar), 
7.01-7.12 (m, 6H, Ar), 7.28-7.39 (m, 4H, Ar); 13C NMR (125 
MHz, CDCl3) δ 69.1 (d, J = 2.4 Hz), 103.1, 108.2, 113.6 (d, J = 
22.8 Hz), 116.3 (d, J = 21.6 Hz), 117.1, 118.9, 120.1, 123.1, 
124.4, 125.0, 126.0 (d, J = 8.4 Hz), 126.5, 126.8, 128.3 (d, J = 
7.2 Hz), 128.7 (d, J = 2.4 Hz), 129.4, 131.9, 132.5, 134.4, 137.6, 
138.1, 141.7, 141.9 (d, J = 2.4 Hz), 161.2 (d, J = 244.7 Hz); 
HRMS (FAB) calcd for C25H17BrFN2 (MH+): 443.0560; found: 
443.0552. 
4.3.5. 13-(2-Bromophenyl)-9-methoxy-7,7a-
dihydroisoquinolino[2,1-a]perimidine (3e) (Table 2, entry 4). By 
a procedure identical with that described for the preparation of 3a, 
1e (50 mg, 0.16 mmol) was converted into 3e (51 mg, 71%) by 
the reaction with 1,8-diaminonaphthalene (2) (37.6 mg, 0.24 
mmol) and CuI (3.0 mg, 0.016 mmol): yellow amorphous solid; 
1H NMR (500 MHz, CDCl3) δ 3.84 (s, 3H, OCH3), 4.54 (br s, 1H, 
NH), 5.68 (s, 1H, NCHN), 6.09 (s, 1H, C=CH), 6.30 (d, J = 7.4 
Hz, 1H, Ar), 6.68 (dd, J = 6.9, 1.1 Hz, 1H, Ar), 6.89-6.91 (m, 2H, 
Ar), 6.93 (dd, J = 8.0, 8.0 Hz, 1H, Ar), 7.03-7.06 (m, 1H, Ar), 
7.09-7.11 (m, 3H, Ar), 7.26-7.34 (m, 3H, Ar), 7.39 (d, J = 8.0 Hz, 
1H, Ar); 13C NMR (125 MHz, CDCl3) δ 55.5, 69.5, 103.9, 107.8, 
112.2, 114.9, 116.8, 118.6, 120.0, 122.7, 124.6, 125.1, 125.5, 
125.8, 126.4, 126.8, 128.3, 129.2, 132.1, 132.5, 134.5, 138.1, 
138.5, 140.5, 142.0, 158.3; HRMS (FAB) calcd for C26H20BrN2O 
(MH+): 455.0759; found: 455.0756. 
4.3.6. 13-(2-Bromophenyl)-8-fluoro-7,7a-
dihydroisoquinolino[2,1-a]perimidine (3f) (Table 2, entry 5). By 
a procedure identical with that described for the preparation of 3a, 
1f (50 mg, 0.17 mmol) was converted into 3f (65 mg, 89%) by 
the reaction with 1,8-diaminonaphthalene (2) (39.1 mg, 0.25 
mmol) and CuI (3.1 mg, 0.017 mmol): yellow amorphous solid; 
1H NMR (500 MHz, CDCl3) δ 4.53 (br s, 1H, NH), 5.62 (d, J = 
1.7 Hz, 1H, NCHN), 6.33 (br s, 1H, Ar), 6.46 (s, 1H, C=CH), 
6.70 (dd, J = 6.9, 1.7 Hz, 1H, Ar), 6.89-6.95 (m, 3H, Ar), 7.05-
7.08 (m, 2H, Ar), 7.27-7.33 (m, 3H, Ar), 7.38-7.40 (m, 2H, Ar); 
13C NMR (125 MHz, CDCl3) δ 64.3, 102.2, 107.8, 112.2 (d, J = 
21.6 Hz), 113.0 (d, J = 15.6 Hz), 117.6, 118.7, 120.0 (d, J = 2.4 
Hz), 123.6, 124.4, 124.8, 126.5, 126.8, 129.4, 130.6 (d, J = 9.6 
Hz), 131.8, 132.4, 134.4, 134.6 (d, J = 4.8 Hz), 137.5, 138.1, 
140.9, 142.6, 143.5, 159.9 (d, J = 245.9 Hz); HRMS (FAB) calcd 
for C25H17BrFN2 (MH+): 443.0560; found: 443.0555. 
4.3.7. 13-(2-Bromo-5-fluorophenyl)-7,7a-
dihydroisoquinolino[2,1-a]perimidine (3g) (Table 2, entry 6). By 
a procedure identical with that described for the preparation of 3a, 
1g (50 mg, 0.17 mmol) was converted into 3g (53 mg, 73%) by 
the reaction with 1,8-diaminonaphthalene (2) (39.1 mg, 0.25 
mmol) and CuI (3.1 mg, 0.017 mmol): pale yellow amorphous 
solid; 1H NMR (500 MHz, CDCl3) δ 4.48 (br s, 1H, NH), 5.64 (s, 
1H, NCHN), 6.12 (s, 1H, C=CH), 6.33 (d, J = 7.4 Hz, 1H, Ar), 
6.66 (dd, J = 6.3, 1.7 Hz, 1H, Ar), 6.79 (ddd, J = 8.4, 8.4, 3.2 Hz, 
1H, Ar), 6.89 (br s, 1H, Ar), 6.97 (dd, J = 7.7, 7.7 Hz, 1H, Ar), 
7.13 (d, J = 7.4 Hz, 1H, Ar), 7.21 (ddd, J = 7.4, 7.4, 1.1 Hz, 1H, 
Ar), 7.27-7.34 (m, 5H, Ar), 7.38 (d, J = 7.4 Hz, 1H, Ar); 13C 
NMR (125 MHz, CDCl3) δ 69.3, 103.5, 107.9, 116.6 (d, J = 22.8 
Hz), 116.9, 118.7, 118.9 (d, J = 3.6 Hz), 119.0 (d, J = 22.8 Hz), 
120.2, 123.3, 124.5, 124.9, 126.2, 126.5, 126.6, 126.7, 129.3, 
132.0, 133.7 (d, J = 7.2 Hz), 134.5, 137.6, 140.1 (d, J = 8.4 Hz), 
141.5, 142.0, 161.3 (d, J = 248.3 Hz); HRMS (FAB) calcd for 
C25H17BrFN2 (MH+): 443.0560; found: 443.0560. 
4.3.8. 13-(2-Bromo-5-methylphenyl)-7,7a-
dihydroisoquinolino[2,1-a]perimidine (3h) (Table 2, entry 7). By 
a procedure identical with that described for the preparation of 3a, 
1h (50 mg, 0.17 mmol) was converted into 3h (67 mg, 91%) by 
the reaction with 1,8-diaminonaphthalene (2) (39.6 mg, 0.25 
mmol) and CuI (3.2 mg, 0.017 mmol): yellow amorphous solid; 
1H NMR (500 MHz, CDCl3) δ 2.16 (s, 3H, CCH3), 4.52 (br s, 1H, 
NH), 5.64 (s, 1H, NCHN), 6.15 (s, 1H, C=CH), 6.31 (d, J = 7.4 
Hz, 1H, Ar), 6.67 (dd, J = 6.6, 1.4 Hz, 1H, Ar), 6.87 (dd, J = 8.3, 
2.0 Hz, 1H, Ar), 6.95 (dd, J = 8.0, 8.0 Hz, 1H, Ar), 6.98 (br s, 1H, 
Ar), 7.13 (d, J = 7.4 Hz, 1H, Ar), 7.18-7.22 (m, 2H, Ar), 7.26-
7.33 (m, 4H, Ar), 7.36 (d, J = 8.0 Hz, 1H, Ar); 13C NMR (125 
MHz, CDCl3) δ 20.7, 69.4, 103.2, 107.8, 117.0, 118.6, 120.3, 
121.0, 123.0, 124.3, 124.9, 125.8, 126.4, 126.5, 126.6, 129.3, 
130.2, 132.1, 132.4, 132.6, 134.5, 136.7, 137.9, 138.0, 142.2, 
142.7; HRMS (FAB) calcd for C26H20BrN2 (MH+): 439.0810; 
found: 439.0807. 
4.3.9. 13-Phenyl-7,7a-dihydroisoquinolino[2,1-a]perimidine (3i) 
(Table 2, entry 8). By a procedure identical with that described 
for the preparation of 3a, 1i (50 mg, 0.24 mmol) was converted 
into 3i (76 mg, 91%) by the reaction with 1,8-
diaminonaphthalene (2) (57.5 mg, 0.36 mmol) and CuI (4.6 mg, 
0.024 mmol): pale yellow amorphous solid; 1H NMR (500 MHz, 
CDCl3) δ 4.94 (br s, 1H, NH), 5.80 (s, 1H, NCHN), 6.14 (d, J = 
7.4 Hz, 1H, Ar), 6.55 (br s, 1H, C=CH), 6.77 (d, J = 7.4 Hz, 1H, 
Ar), 6.92 (dd, J = 7.7, 7.7 Hz, 1H, Ar), 7.14 (dd, J = 7.4, 7.4 Hz, 
1H, Ar), 7.18-7.22 (m, 4H, Ar), 7.27-7.32 (m, 5H, Ar), 7.49 (m, 
2H, Ar); 13C NMR (125 MHz, CDCl3) δ 68.3, 107.5, 113.2, 116.7, 
118.2, 120.3 (2C), 124.4 (2C), 125.1, 125.9, 126.6, 126.9, 127.1 
(2C), 128.3 (2C), 128.4 (2C), 133.5, 134.3, 136.6, 138.1, 139.7, 
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144.5; HRMS (FAB) calcd for C25H19N2 (MH+): 347.1548; 
found: 347.1547. 
4.3.10. 13-(p-Tolyl)-7,7a-dihydroisoquinolino[2,1-a]perimidine 
(3j) (Table 2, entry 9). By a procedure identical with that 
described for the preparation of 3a, 1j (50 mg, 0.23 mmol) was 
converted into 3j (75 mg, 91%) by the reaction with 1,8-
diaminonaphthalene (2) (53.8 mg, 0.34 mmol) and CuI (4.3 mg, 
0.023 mmol): yellow amorphous solid; 1H NMR (500 MHz, 
CDCl3) δ 2.33 (s, 3H, CCH3), 4.97 (br s, 1H, NH), 5.76 (s, 1H, 
NCHN), 6.15 (d, J = 7.4 Hz, 1H, Ar), 6.58 (br s, 1H, C=CH), 
6.77 (d, J = 7.4 Hz, 1H, Ar), 6.93 (dd, J = 8.0, 8.0 Hz, 1H, Ar), 
7.08-7.14 (m, 3H, Ar), 7.17-7.21 (m, 4H, Ar), 7.27 (d, J = 7.4 Hz, 
1H, Ar), 7.30 (dd, J = 7.7, 7.7 Hz, 1H, Ar), 7.43 (m, 2H, Ar); 13C 
NMR (125 MHz, CDCl3) δ 21.3, 68.2, 107.5, 112.8, 116.4, 118.1, 
120.0 (2C), 124.2 (2C), 125.0, 126.0, 126.6, 126.8, 126.9 (2C), 
128.2, 129.2 (2C), 132.3, 133.8, 134.2, 138.2, 138.3, 139.6, 
144.7; HRMS (FAB) calcd for C26H21N2 (MH+): 361.1705; 
found: 361.1705. 
4.3.11. General procedure for four-component coupling–
cyclization: synthesis of N-[(7,7a-dihydroisoquinolino[2,1-
a]perimidin-13-yl)methyl]-N-isopropylpropan-2-amine (11a) 
(Table 3, entry 1). A mixture of 2-ethynylbenzaldehyde (8) (30 
mg, 0.23 mmol), paraformaldehyde (9) (13.8 mg, 0.46 mmol), 
diisopropylamine (10a) (65.3 μL, 0.46 mmol), and CuI (4.4 mg, 
0.023 mmol) in dioxane (1.0 mL) was stirred at rt for 1 h. After 
the Mannich-type reaction was completed (monitored by TLC), 
1,8-diaminonaphthalene (2) (109 mg, 0.69 mmol) was added, and 
the mixture was stirred for additional 60 min at 150 °C under 
microwave irradiation (300 W). The mixture was concentrated 
under reduced pressure and purified by column chromatography 
over silica gel with hexane–EtOAc (25:1) to give 11a (46 mg, 
52% yield) as a pale yellow amorphous solid; 1H NMR (500 
MHz, CDCl3) δ 0.68 (d, J = 6.3 Hz, 6H, 2× CCH3), 0.87 (d, J = 
6.3 Hz, 6H, 2× CCH3), 2.88-2.97 (m, 3H, 2× N–CH and N–
CHH), 3.37 (d, J = 16.0 Hz, 1H, N–CHH), 4.25 (br s, 1H, NH), 
5.87 (s, 1H, NCHN), 6.10 (s, 1H, C=CH), 6.58 (dd, J = 5.7, 2.3 
Hz, 1H, Ar), 7.09-7.13 (m, 3H, Ar), 7.21 (d, J = 6.9 Hz, 1H, Ar), 
7.27-7.31 (m, 3H, Ar), 7.36 (dd, J = 7.7, 7.7 Hz, 1H, Ar), 7.57 (d, 
J = 8.6 Hz, 1H, Ar); 13C NMR (125 MHz, CDCl3) δ 20.4 (2C), 
20.5 (2C), 47.5, 48.0 (2C), 70.1, 101.4, 107.3, 118.0, 118.1, 
120.0, 123.7, 124.0, 124.9, 125.5, 126.4 (2C), 126.6, 129.2, 133.2, 
134.7, 138.6, 142.8, 144.0; HRMS (FAB) calcd for C26H30N3 
(MH+): 384.2440; found: 384.2438. 
4.3.12. 13-(Piperidin-1-ylmethyl)-7,7a-dihydroisoquinolino[2,1-
a]perimidine (11b) (Table 3, entry 2). By a procedure identical 
with that described for the preparation of 11a, 8 (30 mg, 0.23 
mmol) was converted into 11b (60 mg, 70%) by the reaction with 
piperidine (10b) (45.6 μL, 0.46 mmol): pale yellow amorphous 
solid; 1H NMR (500 MHz, CDCl3) δ 1.00-1.04 (m, 4H, 2× CH2), 
1.13 (br t, J = 5.4 Hz, 2H, CH2), 2.03-2.16 (m, 4H, 2× NCH2), 
2.73 (d, J = 13.2 Hz, 1H, NCHH), 3.10 (d, J = 13.2 Hz, 1H, N–
CHH), 4.17 (br s, 1H, NH), 5.72 (s, 1H, NCHN), 5.88 (s, 1H, 
C=CH), 6.54 (dd, J = 6.9, 1.1 Hz, 1H, Ar), 7.09 (d, J = 7.4 Hz, 
1H, Ar), 7.13 (ddd, J = 7.4, 7.4, 1.1 Hz, 1H, Ar), 7.19 (d, J = 6.9 
Hz, 1H, Ar), 7.22-7.35 (m, 5H, Ar), 7.55 (dd, J = 7.7, 2.0 Hz, 1H, 
Ar); 13C NMR (125 MHz, CDCl3) δ 24.3, 25.7 (2C), 53.5 (2C), 
60.8, 69.7, 103.1, 107.1, 117.6, 118.1, 120.5, 123.7, 124.0, 125.4 
(2C), 126.3, 126.5, 126.7, 129.2, 132.6, 134.6, 139.5, 141.2, 
142.6; HRMS (FAB) calcd for C25H26N3 (MH+): 368.2127; 
found: 368.2130. 
4.3.13. 4-[(7,7a-Dihydroisoquinolino[2,1-a]perimidin-13-
yl)methyl]morpholine (11c) (Table 3, entry 3). By a procedure 
identical with that described for the preparation of 11a, 8 (30 mg, 
0.23 mmol) was converted into 11c (52 mg, 61%) by the reaction 
with morpholine (10c) (40.2 μL, 0.46 mmol): yellow 
amorphous solid; 1H NMR (500 MHz, CDCl3) δ 1.95 (br m, 2H, 
2× N–CHH), 2.25 (br m, 2H, 2× N–CHH), 2.72 (d, J = 13.2 Hz, 
1H, N–CHH), 2.93-3.00 (m, 4H, 2× OCH2), 3.33 (d, J = 13.2 Hz, 
1H, N–CHH), 4.19 (br s, 1H, NH), 5.72 (s, 1H, NCHN), 5.90 (s, 
1H, C=CH), 6.56 (d, J = 6.9 Hz, 1H, Ar), 7.11 (d, J = 7.4 Hz, 1H, 
Ar), 7.17 (dd, J = 7.2, 7.2 Hz, 1H, Ar), 7.21-7.35 (m, 6H, Ar), 
7.57 (d, J = 8.6 Hz, 1H, Ar); 13C NMR (125 MHz, CDCl3) δ 52.3 
(2C), 60.2, 66.6 (2C), 69.7, 104.0, 107.1, 117.1, 118.1, 120.8, 
123.9, 124.2, 125.3, 125.7, 126.6 (2C), 127.0, 129.4, 132.4, 134.7, 
139.8, 140.4, 142.5; HRMS (FAB) calcd for C24H24N3O (MH+): 
370.1919; found: 370.1921. 
4.4. Palladium-catalyzed C–H arylation 
4.4.1. General procedure: synthesis of 
dibenzo[1,2:7,8]quinolizino[3,4,5,6-kla]perimidine (4a) 
hydrochloride (Table 4, entry 15). A mixture of 3a (50 mg, 0.12 
mmol), Pd(OAc)2 (2.7 mg, 0.012 mmol), PPh3 (7.7 mg, 0.029 
mmol), and K3PO4 (50.2 mg, 0.24 mmol) in DMF (1.5 mL) was 
stirred for 4 h at 130 °C. The reaction mixture was concentrated 
under reduced pressure and purified by column chromatography 
over silica gel with toluene–EtOAc (200:1) to give 4a (32 mg, 
78%) as a red solid. When the C–H arylation products were 
poorly soluble in various organic solvents, their hydrochlorides 
were prepared as follows: the solid was dissolved in CHCl3, and 
4N solution of HCl in dioxane was added to the mixture. The 
precipitates were collected by filtration to give 4a·HCl as a 
brown solid: mp 124–126 °C; 1H NMR (500 MHz, CD3OD, 
60 °C) δ 6.58 (d, J = 7.4 Hz, 1H, Ar), 6.69 (d, J = 6.9 Hz, 1H, 
Ar), 6.74-6.79 (m, 2H, Ar), 6.93 (br s, 2H, Ar), 7.19 (d, J = 8.0 
Hz, 1H, Ar), 7.25 (br s, 1H, Ar), 7.44-7.50 (m, 3H, Ar), 7.58 (br s, 
1H, Ar), 7.67 (dd, J = 6.6, 6.6 Hz, 1H, Ar), 8.18 (d, J = 8.0 Hz, 
1H, Ar); 13C NMR (125 MHz, CD3OD, 60 °C) δ 110.9, 111.2, 
116.1, 116.9, 119.7, 122.5, 123.4, 123.8, 124.7, 125.6, 125.7, 
126.8, 128.1, 128.4, 129.2, 131.0, 131.2, 131.3, 133.0 (2C), 134.8, 
134.9, 137.1, 137.2, 148.9; HRMS (FAB) calcd for C25H15N2 
(MH+): 343.1235; found: 343.1233. 
4.4.2. 12-Fluorodibenzo[1,2:7,8]quinolizino[3,4,5,6-
kla]perimidine (4b) (Table 5, entry 1). A mixture of 3b (30 mg, 
0.068 mmol), Pd(OAc)2 (1.5 mg, 0.007 mmol), PPh3 (4.4 mg, 
0.017 mmol), and K3PO4 (28.7 mg, 0.14 mmol) in DMF (1.0 mL) 
was stirred for 4 h at 130 °C. The reaction mixture was 
concentrated under reduced pressure and purified by column 
chromatography over silica gel with toluene–EtOAc (200:1) to 
give 4b including some impurities. Recrystallization from 
pyridine gave pure 4b (11 mg, 45%) as red crystals: mp 298–
300 °C; 1H NMR (500 MHz, CDCl3, 60 °C) δ 6.57 (s, 1H, Ar), 
6.63 (d, J = 7.4 Hz, 1H, Ar), 6.79 (dd, J = 4.6, 4.6 Hz, 1H, Ar), 
6.90 (dd, J = 8.3, 8.3 Hz, 2H, Ar), 7.09-7.14 (m, 2H, Ar), 7.22-
7.28 (m, 1H, Ar), 7.36 (dd, J = 7.4, 7.4 Hz, 1H, Ar), 7.56 (d, J = 
9.2 Hz, 1H, Ar), 7.70 (d, J = 8.0 Hz, 1H, Ar), 7.75 (d, J = 8.0 Hz, 
1H, Ar), 8.33 (dd, J = 8.9, 6.0 Hz, 1H, Ar); 13C NMR assignment 
was difficult due to the poor solubility of 4b as well as C–F 
couplings; HRMS (FAB) calcd for C25H14FN2 (MH+): 361.1141; 
found: 361.1143. 
4.4.3. 12-Methyldibenzo[1,2:7,8]quinolizino[3,4,5,6-
kla]perimidine (4c) hydrochloride (Table 5, entry 2). By a 
procedure identical with that described for the preparation of 4b, 
3c (30 mg, 0.068 mmol) was converted into 4c (13 mg, 53%) by 
the reaction with Pd(OAc)2 (1.5 mg, 0.007 mmol), PPh3 (4.5 mg, 
0.017 mmol), and K3PO4 (29.0 mg, 0.14 mmol) as red crystals. 
The crystals were dissolved in CHCl3, and 4N solution of HCl in 
dioxane was added to the mixture. After hexane was added to the 
mixture, the precipitates were collected by filtration to give 
4c·HCl as a brown solid: mp 128–130 °C; 1H NMR (500 MHz, 
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CD3OD) δ 2.39 (s, 3H, CCH3), 6.61 (d, J = 5.7 Hz, 1H, Ar), 
6.73 (d, J = 8.0 Hz, 1H, Ar), 6.88 (dd, J = 7.4, 7.4 Hz, 1H, Ar), 
6.96 (d, J = 9.2 Hz, 1H, Ar), 7.00 (dd, J = 7.4, 7.4 Hz, 1H, Ar), 
7.07 (dd, J = 7.4, 7.4 Hz, 1H, Ar), 7.17 (s, 1H, Ar), 7.29 (d, J = 
8.0 Hz, 1H, Ar), 7.39 (d, J = 8.6 Hz, 1H, Ar), 7.43-7.45 (m, 2H, 
Ar), 7.60 (d, J = 7.4 Hz, 1H, Ar), 7.97 (d, J = 8.0 Hz, 1H, Ar); 
13C NMR (125 MHz, CD3OD) δ 22.1, 110.3, 110.9, 113.9, 116.9, 
119.5, 122.6, 123.5, 123.7, 124.7, 125.4, 125.5, 126.9, 128.0, 
128.3, 128.4, 130.9, 131.2, 132.9, 133.0, 133.1, 134.9, 135.0, 
137.1, 148.5, 149.3; HRMS (FAB) calcd for C26H17N2 (MH+): 
357.1392; found: 357.1390. 
4.4.4. 13-Fluorodibenzo[1,2:7,8]quinolizino[3,4,5,6-
kla]perimidine (4d) (Table 5, entry 3). By a procedure identical 
with that described for the preparation of 4b, 3d (30 mg, 0.068 
mmol) was converted into 4d (13 mg, 53%) by the reaction with 
Pd(OAc)2 (1.5 mg, 0.007 mmol), PPh3 (4.4 mg, 0.017 mmol), 
and K3PO4 (28.7 mg, 0.14 mmol) as red crystals: mp 283–
285 °C; 1H NMR (500 MHz, CDCl3, 60 °C) δ 6.60-6.62 (m, 2H, 
Ar), 6.87 (d, J = 8.0 Hz, 1H, Ar), 7.06-7.16 (m, 4H, Ar), 7.20 (dd, 
J = 8.3, 8.3 Hz, 1H, Ar), 7.32 (dd, J = 7.7, 7.7 Hz, 1H, Ar), 7.52 
(d, J = 9.2 Hz, 1H, Ar), 7.66 (dd, J = 8.0, 2.9 Hz, 1H, Ar), 7.71 (d, 
J = 8.0 Hz, 1H, Ar), 7.98 (dd, J = 10.3, 2.3 Hz, 1H, Ar); 13C 
NMR assignment was difficult due to the poor solubility of 4d as 
well as C–F couplings; HRMS (FAB) calcd for C25H14FN2 
(MH+): 361.1141; found: 361.1140. 
4.4.5. 13-Methoxydibenzo[1,2:7,8]quinolizino[3,4,5,6-
kla]perimidine (4e) hydrochloride (Table 5, entry 4). By a 
procedure identical with that described for the preparation of 4b, 
3e (30 mg, 0.066 mmol) was converted into 4e (15 mg, 61%) by 
the reaction with Pd(OAc)2 (1.5 mg, 0.007 mmol), PPh3 (4.3 mg, 
0.017 mmol), and K3PO4 (28.0 mg, 0.13 mmol) as red crystals. 
The crystals were dissolved in CHCl3, and 4N solution of HCl in 
dioxane was added to the mixture. Hexane was added to the 
mixture and the precipitates were collected by filtration to give 
4e·HCl as a brown solid: mp 140–141 °C; 1H NMR (500 MHz, 
CD3OD) δ 4.03 (s, 3H, OCH3), 6.92 (d, J = 6.9 Hz, 1H, Ar), 7.02 
(d, J = 8.0 Hz, 1H, Ar), 7.09 (dd, J = 7.4, 7.4 Hz, 1H, Ar), 7.34 
(m, 2H, Ar), 7.40 (dd, J = 7.4, 7.4 Hz, 1H, Ar), 7.47 (d, J = 9.2 
Hz, 1H, Ar), 7.67 (d, J = 9.2 Hz, 1H, Ar), 7.71 (s, 1H, Ar), 7.79 
(d, J = 9.2 Hz, 1H, Ar), 7.85 (m, 1H, Ar), 7.91 (s, 1H, Ar), 7.96 
(d, J = 7.4 Hz, 1H, Ar); 13C NMR (125 MHz, CD3OD) δ 57.3, 
104.5, 110.5, 110.9, 117.9, 118.1, 120.8, 123.1, 123.6, 123.9, 
125.7, 126.1, 127.7, 127.8, 128.1, 129.1, 131.0, 131.3, 132.7, 
132.8, 132.9, 134.1, 134.4, 135.7, 148.7, 162.6; HRMS (FAB) 
calcd for C26H17N2O (MH+): 373.1341; found: 373.1341. 
4.4.6. 14-Fluorodibenzo[1,2:7,8]quinolizino[3,4,5,6-
kla]perimidine (4f) hydrochloride (Table 5, entry 5). By a 
procedure identical with that described for the preparation of 4b, 
3f (30 mg, 0.068 mmol) was converted into 4f (13 mg, 51%) by 
the reaction with Pd(OAc)2 (1.5 mg, 0.007 mmol), PPh3 (4.4 mg, 
0.017 mmol), and K3PO4 (28.7 mg, 0.14 mmol) as red crystals. 
The crystals were dissolved in CHCl3, and 4N solution of HCl in 
dioxane was added to the mixture. After hexane was added to the 
mixture, the precipitates were collected by filtration to give 
4f·HCl as a brown solid: mp 130–131 °C; 1H NMR (500 MHz, 
CD3OD, 50 °C) δ 6.75 (d, J = 7.4 Hz, 1H, Ar), 7.07 (d, J = 8.0 
Hz, 1H, Ar), 7.16 (dd, J = 8.0, 8.0 Hz, 1H, Ar), 7.31-7.34 (m, 2H, 
Ar), 7.38 (dd, J = 7.4, 7.4 Hz, 1H, Ar), 7.44 (dd, J = 14.0, 7.7 Hz, 
1H, Ar), 7.61 (d, J = 8.0 Hz, 1H, Ar), 7.81 (d, J = 9.2 Hz, 1H, Ar), 
7.86-7.89 (m, 2H, Ar), 8.00 (s, 1H, Ar), 8.07 (d, J = 8.0 Hz, 1H, 
Ar); 13C NMR (125 MHz, CD3OD, 50 °C) δ 107.3 (d, J = 7.2 Hz), 
110.5, 111.7, 116.7 (d, J = 22.8 Hz), 117.6, 120.6, 123.2, 123.9, 
124.4, 125.2, 125.7 (d, J = 3.6 Hz), 126.4, 128.1, 128.3, 129.5, 
131.2, 131.5, 133.1, 133.6, 135.5, 136.7, 138.6 (d, J = 10.8 Hz), 
139.7 (d, J = 8.4 Hz), 148.7, 160.8 (d, J = 257.9 Hz); HRMS 
(FAB) calcd for C25H14FN2 (MH+): 361.1141; found: 361.1143. 
4.4.7. 8-Fluorodibenzo[1,2:7,8]quinolizino[3,4,5,6-
kla]perimidine (4g) hydrochloride (Table 5, entry 6). By a 
procedure identical with that described for the preparation of 4b, 
3g (30 mg, 0.068 mmol) was converted into 4g (12 mg, 49%) by 
the reaction with Pd(OAc)2 (1.5 mg, 0.007 mmol), PPh3 (4.4 mg, 
0.017 mmol), and K3PO4 (28.7 mg, 0.14 mmol) as red crystals. 
The crystals were dissolved in CHCl3, and 4N solution of HCl in 
dioxane was added to the mixture. After hexane was added to the 
mixture, the precipitates were collected by filtration to give 
4g·HCl as a brown solid: mp 280–281 °C; 1H NMR (500 MHz, 
CD3OD, 60 °C) δ 6.75 (d, J = 6.9 Hz, 1H, Ar), 6.83 (d, J = 8.0 
Hz, 1H, Ar), 6.93-6.98 (m, 2H, Ar), 7.05 (d, J = 8.6 Hz, 1H, Ar), 
7.46 (d, J = 9.2 Hz, 1H, Ar), 7.55-7.58 (m, 3H, Ar), 7.64-7.67 (m, 
2H, Ar), 7.75 (dd, J = 7.4, 7.4 Hz, 1H, Ar), 8.25 (d, J = 8.0 Hz, 
1H, Ar); 13C NMR (125 MHz, CD3OD, 60 °C) δ 110.9, 111.6, 
111.9 (d, J = 25.2 Hz), 116.3, 117.5, 120.4, 120.8 (d, J = 22.8 
Hz), 122.7, 123.7, 124.4, 125.7, 126.6 (d, J = 8.4 Hz), 127.6 (d, J 
= 8.4 Hz), 127.8, 129.0, 129.1, 129.2, 131.0, 131.2, 134.4, 135.2, 
136.9, 137.0, 149.7, 164.5 (d, J = 250.7 Hz); HRMS (FAB) calcd 
for C25H14FN2 (MH+): 361.1141; found: 361.1141. 
4.4.8. 8-Methyldibenzo[1,2:7,8]quinolizino[3,4,5,6-
kla]perimidine (4h) hydrochloride (Table 5, entry 7). By a 
procedure identical with that described for the preparation of 4b, 
3h (30 mg, 0.068 mmol) was converted into 4h (15 mg, 62%) by 
the reaction with Pd(OAc)2 (1.5 mg, 0.007 mmol), PPh3 (4.5 mg, 
0.017 mmol), and K3PO4 (29.0 mg, 0.14 mmol) as red crystals. 
The crystals were dissolved in CHCl3, and 4N solution of HCl in 
dioxane was added to the mixture. After hexane was added to the 
mixture, the precipitates were collected by filtration to give 
4h·HCl as a brown solid: mp 165–166 °C; 1H NMR (500 MHz, 
CD3OD, 60 °C) δ 2.22 (s, 3H, Ar), 6.79 (d, J = 7.4 Hz, 1H, Ar), 
6.89 (d, J = 8.0 Hz, 1H, Ar), 7.00-7.04 (m, 2H, Ar), 7.09 (d, J = 
8.6 Hz, 1H, Ar), 7.50-7.53 (m, 2H, Ar), 7.59-7.63 (m, 3H, Ar), 
7.74-7.80 (m, 2H, Ar), 8.25 (d, J = 8.6 Hz, 1H, Ar); 13C NMR 
(125 MHz, CD3OD, 60 °C) δ 21.6, 110.4, 110.9, 116.7, 117.3, 
120.5, 122.7, 123.6, 123.8, 125.2, 125.5, 125.7, 127.9, 128.9, 
129.1, 130.8, 131.0, 133.9 (2C), 134.3, 135.2, 135.5, 136.9, 137.5, 
142.0, 149.7; HRMS (FAB) calcd for C26H17N2 (MH+): 
357.1392; found: 357.1390. 
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